There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]
Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]
Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in [...]
UPDATE June &, 2016 4:30 PM EST We won. The Durbin Amendment to save all cancer research funding at the Department of Defense passed 66-32, saving the Congressionally Directed Medical Research Program (CDMRP), which includes an important prostate cancer funding resource. Thank you to everyone from Malecare Cancer Support and all of our partner organizations [...]
When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently. Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]
Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an [...]
In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes. We all have these two genes which, when they mutate, are associated with breast, ovarian and prostate cancers. If Myriad succeeded, they would have controlled patents on these genes [...]
As drugs are developed they are given many different names, but the drug (or treatment) is the same despite its name. For us laymen, multiple names for the same drug is confusing. So, why are there so many different names for the same thing? Drugs usually have three different names; A chemical name that relates [...]
Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men with very low–risk prostate cancer. However, There is still too few high-quality comparative effectiveness studies evaluating the incremental risks associated [...]
Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the Department of Defense Prostate Cancer Research Program (DoD PCRP), but to increase its funding for the next fiscal year. I [...]
